When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...

New weight-loss medications are reshaping U.S. healthcare by increasing diagnoses of obesity-related conditions and encouraging patients' engagement with health services. These drugs, including Wegovy ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The dip was slight but was the first such decline in a decade. Separately, a study links Ozempic with an increased risk of a rare form of vision loss, and another study links seed oils with an ...